4//SEC Filing
McInaw Michael 4
Accession 0001192482-20-000125
CIK 0001138776other
Filed
Feb 4, 7:00 PM ET
Accepted
Feb 5, 4:24 PM ET
Size
18.6 KB
Accession
0001192482-20-000125
Insider Transaction Report
Form 4
McInaw Michael
Interim CFO
Transactions
- Disposition to Issuer
Stock Option (Right to Purchase)
2020-02-03−1,500→ 0 totalExercise: $4.91Exp: 2027-02-17→ Common Stock (1,500 underlying) - Disposition to Issuer
Stock Option (Right to Purchase)
2020-02-03−26,250→ 0 totalExercise: $1.55Exp: 2028-04-17→ Common Stock (26,250 underlying) - Disposition to Issuer
Stock Option (Right to Purchase)
2020-02-03−5,000→ 0 totalExercise: $1.32Exp: 2027-08-11→ Common Stock (5,000 underlying) - Disposition to Issuer
Common Stock
2020-02-03−16,107→ 16,107 total - Disposition to Issuer
Stock Option (Right to Purchase)
2020-02-03−5,000→ 0 totalExercise: $1.24Exp: 2027-06-02→ Common Stock (5,000 underlying) - Disposition to Issuer
Stock Option (Right to Purchase)
2020-02-03−6,500→ 0 totalExercise: $1.52Exp: 2028-01-22→ Common Stock (6,500 underlying) - Disposition to Issuer
Stock Option (Right to Purchase)
2020-02-03−6,500→ 0 totalExercise: $5.77Exp: 2026-07-29→ Common Stock (6,500 underlying)
Footnotes (7)
- [F1]Disposed of as a result of the merger pursuant to the previously announced Agreement and Plan of Merger and Reorganization by and among Cerecor Inc. ("Cerecor"), Genie Merger Sub, Inc., Second Genie Merger Sub, LLC and issuer (the "Merger"). At the effective time of the Merger, holders of issuer common stock received (A) the fraction of a share of Cerecor common stock equal to the exchange ratio of 0.0334 (B) one contingent value right, which represents the right to receive contingent payments upon the achievement of certain milestones and (C) cash in lieu of any fractional shares of Cerecor common stock.
- [F2]This option, which became exercisable on July 29, 2017, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
- [F3]This option, which became exercisable on February 17, 2018, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
- [F4]This option, which became exercisable on June 2, 2018, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
- [F5]This option, which became exercisable on August 11, 2018, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
- [F6]This option, which became exercisable on April 17, 2019, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
- [F7]This option, which became exercisable on March 30, 2018, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
Documents
Issuer
Aevi Genomic Medicine, Inc.
CIK 0001138776
Entity typeother
Related Parties
1- filerCIK 0001778747
Filing Metadata
- Form type
- 4
- Filed
- Feb 4, 7:00 PM ET
- Accepted
- Feb 5, 4:24 PM ET
- Size
- 18.6 KB